600511 國藥股份
按盤價 
26.840 -0.310 (-1.142%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 26,728,337 | 4.27% | 52,468,281 | 50,597,450 | 49,696,046 | 45,498,584 | |
| 減：營業總成本 | 25,739,070 | 4.45% | 50,383,129 | 48,403,887 | 47,194,089 | 43,218,513 | |
| 其中:營業成本 | 25,130,711 | 4.45% | 49,008,443 | 47,002,226 | 45,704,776 | 41,676,318 | |
| 財務費用 | (8,550) | -31.37% | (21,877) | (68,030) | (126,127) | (28,840) | |
| 資產減值損失 | (47,379) | 477.27% | (5,564) | (1,066) | 389 | (5,140) | |
| 公允價值變動收益 | -- | -- | 66 | (18,202) | 10,817 | -- | |
| 投資收益 | 286,926 | -2.27% | 566,777 | 514,166 | 358,952 | 291,622 | |
| 其中：對聯營企業和合營企業的投資收益 | 265,949 | -2.37% | 546,994 | 515,180 | 456,539 | 380,800 | |
| 營業利潤 | 1,170,834 | -4.74% | 2,621,664 | 2,677,422 | 2,944,358 | 2,694,923 | |
| 利潤總額 | 1,142,821 | -6.83% | 2,600,143 | 2,653,612 | 2,930,890 | 2,687,886 | |
| 減：所得稅費用 | 268,572 | 14.24% | 510,739 | 523,832 | 596,420 | 559,181 | |
| 淨利潤 | 874,249 | -11.82% | 2,089,404 | 2,129,781 | 2,334,471 | 2,128,705 | |
| 減：非控股權益 | (5,521) | -112.86% | 92,810 | 129,654 | 188,472 | 164,648 | |
| 股東淨利潤 | 879,769 | -7.25% | 1,996,593 | 2,000,127 | 2,145,999 | 1,964,058 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 1.166 | -7.25% | 2.646 | 2.651 | 2.844 | 2.603 | |
| 每股派息 (元) * | -- | -- | 0.800 | 0.800 | 0.854 | 0.782 | |
| 每股淨資產 (元) * | 24.931 | 7.65% | 24.579 | 22.701 | 20.909 | 18.840 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 20/08/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
